How Much Is AOP Orphan Pharmaceuticals Sweden AB Worth?
AOP Orphan Pharmaceuticals Sweden AB - Company Valuation
Enterprise Value
31,537,695 kr
How This Is Valued
- Capitalised Earnings (EV/EBITDA)
- 31,537,695 kr
- Revenue Multiple
- 27,031,052 kr
- Range
- 24,749,236 kr–41,605,487 kr
- Evidence Strength
- Low
- Based on FY
- 2025
- Valuation Date
- Business Strength
- B+
- Altman Z″
- 6.17
- Risks
- Insufficient Data
Scope & Evidence
- Company
- AOP Orphan Pharmaceuticals Sweden AB
- Registration
- SE · 5591698708
- Covers
- Not stated in the filing
- Filings Used
- 4 · FY 2025, 2024, 2023, 2022
Valuation by Method
Capitalised Earnings (EV/EBITDA)
31.5m kr
Revenue Multiple
27m kr
0 kr
8m kr
16m kr
24m kr
32m kr
Industry: NACE 46 · 2 Europe industry cohorts
Methodology & Assumptions
- Maintainable EBITDA
- 2,840,319 kr
- Industry EV / EBITDA
- 11.1×
- EV / EBITDA Multiple
- 11.1×
- Industry Revenue Multiple
- 0.76×
- Revenue Multiple
- 0.76×
- Enterprise Value
- 31,537,695 kr
- Net Debt
- -6,248,587 kr
- Value Before Discount
- 31,537,695 kr
Key Ratios
- Current Ratio
- 1.81×
- Quick Ratio
- -
- Debt / Equity
- 1.18×
- Equity Ratio
- 45.9%
- Interest Coverage
- ≥ 100.00×
- Gross Margin
- -
- Net Profit Margin
- 5.3%
- Return on Equity
- 35.3%
- Return on Assets
- 16.2%
- Revenue CAGR
- 13.8%
Asset Distribution
Fixed AssetsCashReceivablesOther Assets
Liability Maturity
Short-Term
3-Year Revenue Scenarios
80m kr
60m kr
40m kr
20m kr
0 kr
202620272028
OptimisticBaseConservative
Revenue vs Industry Peers
- Swedish Orphan Biovitrum AB (publ)
- 15,529,000,000 kr
- Evolan Pharma AB
- 1,186,465,691 kr
- AOP Orphan Pharmaceuticals Sweden AB ★
- 40,409,270 kr
- MEDFOUR AB
- 26,729,010 kr
Revenue, Profit & EBITDA
60m kr
45m kr
30m kr
15m kr
0 kr
2022202320242025
RevenueEBITDANet Profit
Versus Industry Median
60m kr
45m kr
30m kr
15m kr
0 kr
RevenueNet Profit
This CompanyIndustry Median